quarterly

  1. D59
    1,338 Posts.
    Looking at the quarterly and accelerating cashburn with trials, it seems to me they've got a window of about 12 months within which they'll have to cut a partnership/licensing deal with a pharma or else tap the market for more money. That is, of course, unless they get taken out first.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.